Royo, Romina
Magnano, Laura http://orcid.org/0000-0002-6928-8386
Delgado, Julio
Ruiz-Gil, Sara
Gelpí, Josep Ll.
Heyn, Holger http://orcid.org/0000-0002-3276-1889
Taylor, Malcom A. http://orcid.org/0000-0002-7818-7595
Stankovic, Tatjana
Puente, Xose S. http://orcid.org/0000-0001-9525-1483
Nadeu, Ferran http://orcid.org/0000-0003-2910-9440
Campo, Elías http://orcid.org/0000-0001-9850-9793
Article History
Received: 11 May 2022
Revised: 13 May 2022
Accepted: 25 May 2022
First Online: 7 June 2022
Change Date: 5 December 2022
Change Type: Update
Change Details: Unnecessary texts have been removed.
Change Date: 6 December 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41408-022-00762-x
Competing interests
: HH is co-founder of Omniscope and consultant to MiRXES. XSP is co-founder of and holds an equity stake in DREAMgenics. FN has received honoraria from Janssen for speaking at educational activities. EC has been a consultant for Takeda, NanoString, AbbVie, and Illumina; has received honoraria from Janssen, EUSPharma, and Roche for speaking at educational activities; and is an inventor on a Lymphoma and Leukemia Molecular Profiling Project patent “Method for subtyping lymphoma subtypes by means of expression profiling” (PCT/US2014/64161) not related to this project. The remaining authors declare no competing interests.